Targeting nanoparticles to cancer.

By Ming Wang, Maya Thanou. Pharmacological Research, 2010

881 citations recorded by the source corpus.

Subfields: Biomaterials, Molecular Biology, Polymers and Plastics

View Paper: https://www.semanticscholar.org/paper/ecefbda894fb3d093bcea304be0f214b983b6e23

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Molecular Biology

In Polymers and Plastics

Citations in the corpus

Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive oxygen species (2012, background): “Discussion Nanomedicine aims to overcome the problems related to human diseases at the nanoscale level, where most of the biological molecules exist and operate.(42) Physicochemical characterization of nanoscale materials is essential in biomedical research for better interpretation of results.”
Current trends in the use of liposomes for tumor targeting (2013, background): “PEG molecules form a protective hydrophilic layer on the surface of the liposomes that prevents their aggregation and interaction with the blood components [16].”
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. (2013, background): “Nanoparticles are cleared largely by the RES [3, 51, 52].”
PLGA-based nanoparticles: an overview of biomedical applications. (2012, background): “As a sufficient PEG coating is essential for avoiding recognition by the RES, ligands should be extended away from the nanoparticle surfaces to avoid shielding by the PEG chains [10].”
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, methodology): “Thus, PEG chain length and concentration plays an important role in determining: 1) an effective liposome preparation; 2) the PEG configuration; 3) liposome size; 4) encapsulation of drug; 5)membrane permeability; 6) liposomal stability; and 7) the effectiveness of PEG as a protective layer (Torchil”
Assessment of the Evolution of Cancer Treatment Therapies (2011, background): “As an example, the recognition of PEGylated liposomes by anti-PEG antibodies has been reported to occur between 2 to 4 days after the first administration of PEG-liposomes, leading to fast clearance from circulation [54].”
Nanomedicine therapeutic approaches to overcome cancer drug resistance (2013, background): “Further, these tumors have dysfunctional lymphatic drainage, which also results in drug accumulation [78].”
Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. (2011, background): “The consequences of such effects in nanoparticle therapies based on explicit cancer cell targeting or the leaky vasculature of tumours (enhanced permeability effect”
An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites (2019, background): “This might be achievable by efficient delivery of anticancer agents into TME and thereby tumour cells.([5,6]) On the other hand, the formulated NPs must pass through several physiological and biological barriers.”